Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysisResearch in context
Summary: Background: Although 13-valent pneumococcal conjugate vaccine (PCV13) is available in China's private market, it has yet to be introduced into the National Immunization Programme (NIP) and is therefore not available to large parts of the population. This study aimed to estimate the co...
Main Authors: | Xiaozhen Lai, Cristina Garcia, Dan Wu, Maria Deloria Knoll, Haijun Zhang, Tingting Xu, Rize Jing, Zundong Yin, Brian Wahl, Hai Fang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | The Lancet Regional Health. Western Pacific |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666606522002814 |
Similar Items
-
Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine
by: Matt Wasserman, et al.
Published: (2018-01-01) -
Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01) -
Molecular characteristics and antimicrobial resistance of invasive pneumococcal isolates from children in the post-13-valent pneumococcal conjugate vaccine era in Shenzhen, China
by: Lu Huang, et al.
Published: (2024-03-01) -
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01) -
Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-03-01)